Anti-thrombotic strategies for patients with atrial fibrillation and heart failure

Heart Failure Reviews

Volumn 7, Issue 3, 2002, Pages 261-266

  Walsh, Mary Norine ^a   Prystowsky, Eric N ^a  

^a Care Group   (United States)

Author keywords

Anticoagulation; Atrial fibrillation; Congestive heart failure; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; PLACEBO; VASODILATOR AGENT; WARFARIN;

AGE; ANTICOAGULANT THERAPY; BLEEDING; CARDIOMYOPATHY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DOSE RESPONSE; DRUG MONITORING; EPIDEMIOLOGICAL DATA; HEART ATRIUM FIBRILLATION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE FAILURE; HIGH RISK PATIENT; HUMAN; INCIDENCE; INTERNATIONAL STANDARD UNIT; NONHUMAN; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK MANAGEMENT; STROKE; TACHYCARDIA; THROMBOEMBOLISM;

ADULT; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; HEART FAILURE, CONGESTIVE; HUMANS; MIDDLE AGED; PROGNOSIS; WARFARIN;

EID: 0036660186     PISSN: 13824147     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020081327269     Document Type: Review

References (48)

1. Kannel WB, Abbott RD, Savage DD, et al. Epidemiologic features of chronic atrial fibrillation. The Framingham Study. N Engl J Med 1982;306:1018-1022.
2. Ostrander LD Jr, Brandt RL, Kjelsberg MO, Epstein FH. Electrocardiographic findings among the adult population of a total natural community, Tecumseh, Michigan. Circulation 1965;31:888-898.
3. Lake FR, McCall MG, Cullen KJ, et al. Atrial fibrillation and mortality in an elderly population. Aust N Z J Med 1989;19:321-326.
4. Cairns JA, Connolly SJ. Non rheumatic atrial fibrillation. Circulation 1991;84:469-481.
5. Onundarson PT, Thorgeirsson G, Jonmundsson E, Sigfusson N, Hardson Th. Chronic atrial fibrillation - Epidemiologic features and 14 year follow-up: A case control study. Eur Heart J 1987;3:521-527.
6. Carson PE, Johnson GR, Dunkman WB, et al. The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT studies. Circulation 1993;87(suppl VI):VI-102-VI-110.
7. The SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
8. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. N Engl J Med 1992;327:669-677.
9. Middlekauf HR, Stevenson WG, Stevenson LW. Prognostic significance of atrial fibrillation in advanced heart failure. A study of 390 patients. Circulation 1991;84:40-48.
10. Natterson PD, Stevenson WG, Saxon LA, et al. Risk of arterial embolization in 224 patients awaiting cardiac transplantation. Am Heart J 1995;129:564-570.
11. Stevenson WG, Stevenson LW, Middlekauf HR. Improving survival for patients with atrial fibrillation and advanced heart failure. J Am Coll Cardiol 1996;28:1458-1463.
12. Mahoney P, Kimmel S, Denofro D, et al. Prognostic significance of atrial fibrillation in patients at a tertiary medical center referred for heart transplantation because of severe heart failure. Am J Cardiol 1999;83:1544-1547.
13. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987;316:1429-1435.
14. Naito M, David D, Michelson EL, Schaffenburg M, Dreifus LS. The hemodynamic consequences of cardiac arrhythmias: Evaluation of the relative roles of abnormal atrioventricular sequencing, irregularity of ventricular rhythm and atrial fibrillation in a canine model. Am Heart J 1983;106:284.
15. Clark DM, Plumb VJ, Epstein AE, Kay GN. Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fibrillation. J Am Coll Cardiol 1997;30:1039-1045.
16. Brookes CIO, White PA, Staples M, Oldershaw PJ, Redington AN, Collins PD, Noble MIM. Myocardial contractility is not constant during spontaneous atrial fibrillation in patients. Circulation 1998;98:1762-1768.
17. Gosselink ATM, Crijns HJGM, Van Den Berg MP, et al. Functional capacity before and after cardioversion of atrial fibrillation: A controlled study. Br Heart J 1994;72:161-166
18. Upshaw CB Jr. Hemodynamic changes after cardioversion of chronic atrial fibrillation. Arch Intern Med 1997;157:1070-1076.
19. Vanden Berg MP, Tuinenberg AE, van Veldhuisen DJ, de Kam PJ, Crijns HJGM. Cardioversion of atrial fibrillation in the setting of mild to moderate heart failure. International Journal of Cardiology 1998;63:63-70.
20. Prystowsky EN, Katz A. Atrial fibrillation. In: EJ Topol, ed. Textbook of Cardiovascular Medicine. Philadelphia: Lippincott-Raven, 1998.
21. Packer DL, Bardy GH, Worley SJ, Smith MS, Cobb FR, Coleman RE, Gallagher JJ, German LD. Tachycardia-induced cardiomyopathy: A reversible form of left ventricular dysfunction. Am J Cardiol 1986;57:563-570.
22. Phillips E, Levine SA. Auricular fibrillation without other evidence of heart disease: A cause of reversible heart failure. Am J Med 1949;7:478-489.
23. Grogan M, Smith HC, Gersh BJ, Wood DL. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol 1992;69:1570-1573.
24. Keiny JR, Sacrez A, Facello A, et al. Increase in radionuclide left ventricular ejection fraction after cardioversion of chronic atrial fibrillation in idiopathic dilated cardiomyopathy. Eur Heart J 1992;13:1290-1295.
25. Shinbane JS, Wood MA, Jensen DN, Ellenbogen KA, Fitzpatrick AP, Scheinman MM. Tachycardia-induced cardiomyopathy: A review of animal models and clinical studies. J Amer Coll Cardiol 1997;29:709-715.
26. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: A major contributor to stroke in the elderly. The Framingham study. Arch Intern Med 1987;147:1561-1564.
27. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation is an independent risk factor for stroke: The Framingham study. Stroke 1991;22:983-988.
28. Petersen P, Boysen G, Godtfredsen J, et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: The Copenhagen AFASAK study. Lancet 1989;1:175-178.
29. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonreheumatic atrial fibrillation. N Engl J Med 1990;323:1505.
30. Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation: Final results. Circulation 1991;84:527.
31. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992;327:1406-1412.
32. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-1457.
33. Prystowsky EN, Benson W, Jr, Fuster V, et al. Management of patients with atrial fibrillation. A statement for healthcare professionals from the subcommittee on electrophysiology, American Heart Association. Circulation 1996;93:1262-1277.
34. Miller VT, Rothrock JF, Pearce LA, et al. Ischemic stroke in patients with atrial fibrillation: Effect of aspirin according to stroke mechanism: Stroke Prevention in Atrial Fibrillation Investigators. Neurology 1993;43:32-36.
35. Bogousslavsky J, Van Melle G, Regli F, Kappenberger L. Pathogenesis of anterior circulation stroke in patients with nonvalvular atrial fibrillation: The Lausanne Stroke Registry. Neurology 1990;40:1046-1050.
36. Rosenthal MS, Halpern JL. Thromboembolism in nonvalvular atrial fibrillation: The answer may be in the ventricle. Int J Cardiol 1992;37:277-282.
37. Zabalgoitia M, Dipeshkumar KG, McPherson D, Mehlman DJ, Talano JV. Spontaneous echo contrast in severe left ventricular dysfunction: A risk factor for thromboembolism. Circulation 1990;82(suppl.3):III-109. Abstract.
38. The Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation, II: Echocardiographic features of patients at risk. Ann Intern Med 1992;116:6-12.
39. Blackshear JL, Pearce LA, Asinger RW, et al. Mitral regurgitation associated with reduced thromboembolic events in high-risk patients with nonrheumatic atrial fibrillation. Stroke Prevention in Atrial Fibrillation Investigators. Am J Cardiol 1993;72:840-843.
40. The Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation: I. Clinical features of patients at risk. Ann Intern Med 1992;116:1-5.
41. Segal JP, Stapleton JF, McClellan JR, et al. Idiopathic cardiomyopathy: Clinical features, prognosis and therapy. Curr Prob Cardiol 1978;3:1-49.
42. Cioffi G, Pozzoli M, Forni G, et al. Systemic thromboembolism in chronic heart failure. Eur Heart J 1996;17:1381-1389.
43. Dunkman WB, Johnson GR, Carson PE, et al. Incidence of thromboembolic events in congestive heart failure. Circulation 1993;87(suppl. IV):VI-94-VI-101.
44. Connolly SJ, Laupacis A, Gent M, et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) study. J Amer Coll Cardiol 1991;18:349.
45. EAFT Study Group. European Atrial Fibrillation Trial: Secondary prevention of vascular events in patients with non-rheumatic atrial fibrillation and a recent transient ischaemic attack or minor ischaemic stroke. Lancet 1993;342:1255-1262.
46. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high risk patients with atrial fibrillation: Stroke prevention in atrial fibrillation III randomized clinical trial. Lancet 1996;348:633-638.
47. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic arial fibrillation. N Engl J Med 1996;335:540-546.
48. Prystowsky EN. Management of atrial fibrillation: Therapeutic options and clinical decisions. Am J Cardiol 2000;85:3D-11D.